R&D Pipeline

Phase:

Therapy:

Pipeline last updated 29 December 2014
Compound/indication Phase 1 Phase 2 Phase 3 Filed
Saxenda® (Liraglutide 3 mg) (NN8022)

Obesity
G530L (NN9030)

Obesity
NN9838

Obesity
  •